NY-CLARITY-AI
29.10.2020 14:02:13 CET | Business Wire | Press release
Clarity AI announced today that it has closed a USD $15 million funding round led by Deutsche Börse AG and co-investor Mundi Ventures. Clarity AI empowers investors to manage the impact of their portfolios through a proprietary technology platform that leverages big data and machine learning to assess sustainability for all societal stakeholders.
“Our purpose is simple: to measure the impact of companies on our society and planet,” said Rebeca Minguela, Founder and CEO of Clarity AI. “Investors attempting to evaluate impact have faced fragmented and unreliable data, inconsistent subjective definitions, and a lack of standards and tools for comprehensive analysis. Historically it has been too hard and resource-intensive to get accurate and transparent insights. Clarity AI provides a solution for that.”
Since its founding in 2017, Clarity AI has attracted a client network representing in excess of $3 trillion of assets and funding from investors, including Kibo Ventures, Founders Fund, Seaya Ventures and Matthew Freud. The company has built the most reliable tech platform on social and environmental impact, featuring more than 30,000 companies, 198 countries, 187 local governments and over 200,000 funds. The company uses proprietary technology and algorithms to produce transparent assessments for investors that are the most consistent and comprehensive available.
The “Sustainable Investment” market has grown 34% in the last two years and now represents one third of total global assets under management (AUM) – $30.7 trillion (of a total of $79.2 trillion).1 This rapid growth comes as research shows that 81% of investors want to better understand and improve the impact performance of their investments, with millennials (in particular) demanding greater social impact transparency in their portfolios.2
In the last six months, Clarity AI has seen a significant increase in demand for its services, including signing clients with eight times the assets under management as in the preceding period.
Minguela added: “2020 has seen extraordinary volatility and uncertainty – from COVID-19 to social justice protests. It has never been more important for investors to have accurate insights on the true impact of the companies in which they place their trust and their money. That is why we are scaling up our business to enable investors to identify and support those companies helping to solve society’s biggest challenges.”
The $15 million investment will drive Clarity AI’s sustainable expansion plans, including scaling-up investment in proprietary technology and AI, as well as integrating with the world’s largest financial services platforms. This approach will make it even quicker and easier for investors and corporations to analyze and report sustainability and impact.
Deutsche Börse AG led the funding round, underscoring the strong alignment of the Clarity AI product offering with Deutsche Börse’s expanding presence in the sustainability space and the importance of accelerating the growth of a European-focused Impact and ESG technology platform. Clarity AI and Deutsche Börse are also exploring potential collaboration opportunities in various Deutsche Börse business areas, including Qontigo, a leading provider of indices and analytics.
Sebastian Ceria, CEO of Qontigo, said: “This partnership reflects our mutual commitment to the ongoing enhancement of sustainable investing and the application of the latest technology in pursuit of this goal. We were very impressed by Rebeca and her team’s vision for Clarity AI and the advanced technology platform they have created. We are excited to be in a partnership that puts impact at the heart of investment.”
Clarity AI has received widespread recognition for its positive impact and innovative approach, including being selected as a 2020 Technology Pioneer by the World Economic Forum and receiving awards from the Harvard Innovation Lab and funding from Horizon 2020, the European Union’s Research and Innovation program.
Ends
NOTE TO EDITORS
ABOUT CLARITY AI
Clarity AI is a global fintech company that empowers investors to manage the impact of their portfolios through a proprietary technology platform that leverages big data and machine learning to assess sustainability for all societal stakeholders. Founded in 2017 by Rebeca Minguela, Clarity AI has offices in the US, UK and Spain and a client network with over $3T assets under management (AUM). The company has a team of over 100 technology, sustainability and research experts with collective experience from leading organizations, businesses and research institutions including NASA, the World Bank, Google, Netflix, McKinsey & Company, Morgan Stanley, J.P. Morgan, Harvard, M.I.T and more.
Rebeca Minguela is the Founder and CEO of Clarity AI. Previously, she led the Global Digital Transformation Program at Santander Bank after founding and leading Blink Booking, a last-minute hotel booking app acquired by Groupon in 2013, a company she moved to as Senior Director of Product and Technology thereafter. Rebeca has also worked at Bain Capital Private Equity, Boston Consulting Group, German Aerospace Agency, Siemens and IBM. She holds an MBA degree with distinction from Harvard Business School and has won several awards, including Top 25 Women Leaders in Financial Technology in 2019 and 2020, Young Global Leader by the World Economic Forum in 2017 and European Young Leader in 2018.
For more information, visit https://clarity.ai/
ABOUT DEUTSCHE BÖRSE
As an international exchange organisation and innovative market infrastructure provider, Deutsche Börse Group ensures markets characterised by integrity, transparency and stability. With its wide range of products, services and technologies, the Group organises safe and efficient markets for sustainable economies.
Its business areas extend along the entire value chain in exchange trading, including the admission, trading and clearing, and custody of securities and other financial instruments, the dissemination of market data, as well as the management of collateral and liquidity. As a technology company, the Group develops state-of-the-art IT solutions and offers IT systems all over the world.
With around 6,000 employees, the Group has its headquarters in the financial centre of Frankfurt/Rhine-Main, as well as a strong global presence in 38 locations such as Luxembourg, Prague, London, New York, Chicago, Hong Kong, Singapore, Beijing, Tokyo and Sydney.
ABOUT ALMA MUNDI VENTURES
Alma Mundi is a Venture Capital fund investing in B2B tech and Insurtech startups across Europe, the United States and Israel. The investments range from early Seed and Series A, to Series B and later stages. The headquarters are in Madrid and offices in Barcelona, London and Tel Aviv. The portfolio includes startups in London, Paris, Amsterdam, Berlin, Tel Aviv, San Francisco and New York. They bring value to entrepreneurs by leveraging their LPs, leading European insurers, and a global network, called the Mundi Club, which groups more than 750 C-level executives in more than 50 cities worldwide.
1
Gl
obal Asset Management 2018: The Digital Metamorphosis, https://www.bcg.com/publications/2018/global-asset-management-2018-digital-metamorphosis
; Global Sustainable Investment Alliance: 2018 Global Sustainable Investment Review, http://www.gsi-alliance.org/wp-content/uploads/2019/03/GSIR_Review2018.3.28.pdf
2
Har
vard Law School Forum on Corporate Governance: Institutional Investor Survey 2020, https://corpgov.law.harvard.edu/2020/03/25/institutional-investor-survey-2020/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005306/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
